These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11520198)

  • 1. 2-N-acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT2-selective melatonin antagonists.
    Spadoni G; Balsamini C; Diamantini G; Tontini A; Tarzia G; Mor M; Rivara S; Plazzi PV; Nonno R; Lucini V; Pannacci M; Fraschini F; Stankov BM
    J Med Chem; 2001 Aug; 44(18):2900-12. PubMed ID: 11520198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 melatonin receptor partial agonists, antagonists, and putative inverse agonists.
    Spadoni G; Balsamini C; Bedini A; Diamantini G; Di Giacomo B; Tontini A; Tarzia G; Mor M; Plazzi PV; Rivara S; Nonno R; Pannacci M; Lucini V; Fraschini F; Stankov BM
    J Med Chem; 1998 Sep; 41(19):3624-34. PubMed ID: 9733487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new melatonin receptor ligand with mt1-agonist and MT2-antagonist properties.
    Nonno R; Lucini V; Spadoni G; Pannacci M; Croce A; Esposti D; Balsamini C; Tarzia G; Fraschini F; Stankov BM
    J Pineal Res; 2000 Nov; 29(4):234-40. PubMed ID: 11068946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of subtype selective melatonin receptor agonists and antagonists.
    Sugden D; Yeh LK; Teh MT
    Reprod Nutr Dev; 1999; 39(3):335-44. PubMed ID: 10420436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles.
    Faust R; Garratt PJ; Jones R; Yeh LK; Tsotinis A; Panoussopoulou M; Calogeropoulou T; Teh MT; Sugden D
    J Med Chem; 2000 Mar; 43(6):1050-61. PubMed ID: 10737738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, pharmacological characterization and QSAR studies on 2-substituted indole melatonin receptor ligands.
    Mor M; Spadoni G; Di Giacomo B; Diamantini G; Bedini A; Tarzia G; Plazzi PV; Rivara S; Nonno R; Lucini V; Pannacci M; Fraschini F; Stankov BM
    Bioorg Med Chem; 2001 Apr; 9(4):1045-57. PubMed ID: 11354661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the structure-activity relationships of melatonin receptor agonists and antagonists: lengthening the N-acyl side-chain has differing effects on potency on Xenopus melanophores.
    Teh MT; Sugden D
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Nov; 358(5):522-8. PubMed ID: 9840420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand efficacy and potency at recombinant human MT2 melatonin receptors: evidence for agonist activity of some mt1-antagonists.
    Nonno R; Pannacci M; Lucini V; Angeloni D; Fraschini F; Stankov BM
    Br J Pharmacol; 1999 Jul; 127(5):1288-94. PubMed ID: 10455277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.
    Rivara S; Mor M; Silva C; Zuliani V; Vacondio F; Spadoni G; Bedini A; Tarzia G; Lucini V; Pannacci M; Fraschini F; Plazzi PV
    J Med Chem; 2003 Apr; 46(8):1429-39. PubMed ID: 12672242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indole melatonin agonists and antagonists derived by shifting the melatonin side chain from the C-3 to the N-1 or to the C-2 indole position.
    Tarzia G; Diamantini G; Spadoni G
    Biol Signals Recept; 1999; 8(1-2):24-31. PubMed ID: 10085459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
    Rivara S; Lorenzi S; Mor M; Plazzi PV; Spadoni G; Bedini A; Tarzia G
    J Med Chem; 2005 Jun; 48(12):4049-60. PubMed ID: 15943478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
    Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
    J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the melatonin receptor. 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept[b]indoles.
    Davies DJ; Garratt PJ; Tocher DA; Vonhoff S; Davies J; Teh MT; Sugden D
    J Med Chem; 1998 Feb; 41(4):451-67. PubMed ID: 9484496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl)methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo.
    Winczyk K; Pawlikowski M; Lawnicka H; Kunert-Radek J; Spadoni G; Tarzia G; Karasek M
    Neuro Endocrinol Lett; 2002 Apr; 23 Suppl 1():50-4. PubMed ID: 12019352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for the evaluation of drug action at the human melatonin receptor subtypes.
    Nonno R; Fraschini F; Stankov BM
    Biol Signals Recept; 1999; 8(1-2):32-40. PubMed ID: 10085460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular determinants for the differential coupling of Galpha(16) to the melatonin MT1, MT2 and Xenopus Mel1c receptors.
    Lai FP; Mody SM; Yung LY; Kam JY; Pang CS; Pang SF; Wong YH
    J Neurochem; 2002 Mar; 80(5):736-45. PubMed ID: 11948236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The putative melatonin receptor antagonist GR128107 is a partial agonist on Xenopus laevis melanophores.
    Teh MT; Sugden D
    Br J Pharmacol; 1999 Mar; 126(5):1237-45. PubMed ID: 10205014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists.
    Zlotos DP; Attia MI; Julius J; Sethi S; Witt-Enderby PA
    J Med Chem; 2009 Feb; 52(3):826-33. PubMed ID: 19193160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms.
    Dubocovich ML; Yun K; Al-Ghoul WM; Benloucif S; Masana MI
    FASEB J; 1998 Sep; 12(12):1211-20. PubMed ID: 9737724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2 .
    Nosjean O; Nicolas JP; Klupsch F; Delagrange P; Canet E; Boutin JA
    Biochem Pharmacol; 2001 Jun; 61(11):1369-79. PubMed ID: 11331072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.